X Anton Alvarez
Overview
Explore the profile of X Anton Alvarez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alvarez X, Winston C, Barlow J, Sarsoza F, Alvarez I, Aleixandre M, et al.
J Alzheimers Dis
. 2022 Sep;
90(2):705-717.
PMID: 36155516
Background: Plasma neuronal-derived extracellular vesicles (NDEV) contain proteins of pathological, diagnostic, and therapeutic relevance. Objective: We investigated the associations of six plasma NDEV markers with Alzheimer's disease (AD) severity, cognition...
2.
Tran L, Alvarez X, Le H, Nguyen D, Le T, Nguyen N, et al.
CNS Neurol Disord Drug Targets
. 2021 Aug;
21(7):621-630.
PMID: 34414874
Aims: To investigate the efficacy and safety of Cerebrolysin and Cerebrolysin plus nootropics in the routine treatment of patients with acute ischemic stroke (AIS). Background: Acute ischemic stroke (AIS) is...
3.
Alvarez X, Alvarez I, Martinez A, Romero I, Benito C, Suarez I, et al.
Int J Neuropsychopharmacol
. 2020 Jul;
23(9):581-586.
PMID: 32640027
Serum vascular endothelial growth factor (VEGF) increases with Alzheimer's disease (AD) severity and may prevent cognitive decline. However, information on the influence of AD drug therapy on circulating VEGF is...
4.
Alvarez X, Alvarez I, Aleixandre M, Linares C, Muresanu D, Winter S, et al.
J Alzheimers Dis
. 2018 May;
63(3):1003-1013.
PMID: 29710700
Vascular endothelial growth factor (VEGF) is an angioneurin involved in the regulation of vascular and neural functions relevant for the pathophysiology of Alzheimer's disease (AD), but the influence of AD...
5.
Alvarez X, Alvarez I, Iglesias O, Crespo I, Figueroa J, Aleixandre M, et al.
Int J Neuropsychopharmacol
. 2016 May;
19(6).
PMID: 27207906
Background: Low circulating brain derived neurotrophic factor may promote cognitive deterioration, but the effects of neurotrophic and combination drug therapies on serum brain derived neurotrophic factor were not previously investigated...
6.
Alvarez X, Fuentes P
Drugs Today (Barc)
. 2011 Oct;
47(7):487-513.
PMID: 22013558
Cerebrolysin is a neuropeptide preparation mimicking the action of endogenous neurotrophic factors. Positive effects of Cerebrolysin on β-amyloid- and tau-related pathologies, neuroinflammation, neurotrophic factors, oxidative stress, excitotoxicity, neurotransmission, brain metabolism,...
7.
Rockenstein E, Ubhi K, Pham E, Michael S, Doppler E, Novak P, et al.
J Neurosci Res
. 2011 Jul;
89(11):1812-21.
PMID: 21793038
Neurodegenerative disorders such as Alzheimer's disease (AD) are characterized by the loss of neurotrophic factors, and experimental therapeutical approaches to AD have investigated the efficacy of replacing or augmenting neurotrophic...
8.
Alvarez X, Cacabelos R, Sampedro C, Couceiro V, Aleixandre M, Vargas M, et al.
Curr Alzheimer Res
. 2011 Jun;
8(5):583-91.
PMID: 21679156
Treatment with neurotrophic agents might enhance and/or prolong the effects of cholinesterase inhibitors (ChEIs) in Alzheimer's disease (AD). We compared the safety and efficacy of the neurotrophic compound Cerebrolysin (10...
9.
Muresanu D, Alvarez X, Moessler H, Novak P, Stan A, Buzoianu A, et al.
J Neurol Sci
. 2010 Oct;
299(1-2):179-83.
PMID: 20923712
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised,...
10.
Alvarez X, Sampedro C, Cacabelos R, Linares C, Aleixandre M, Garcia-Fantini M, et al.
Int J Neuropsychopharmacol
. 2009 Jun;
12(7):867-72.
PMID: 19531281
According to current scientific knowledge, excess tumour necrosis factor-α (TNF-α) and low insulin-like growth factor-I (IGF-I) are pathogenic-risk factors that constitute therapeutic targets for Alzheimer's disease (AD). Changes in serum...